- Home
Clinical trials
Search for a clinical trial
Filter
Search for a clinical trial
149 result(s)
- ENT/Head and Neck CancersParis219885 GALAXIES H&N-202A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
CHRISTOPHE LE TOURNEAU
- Colorectal cancerSaint-CloudADAGE - Prodige 34Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.
- SarcomasParisADCT-601-102A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.
SARAH WATSON
- Saint-CloudAIPACAIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
ETIENNE BRAIN
- Lung cancerParisAK112-301-HARMONiA randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.
NICOLAS GIRARD
- Breast cancerParis, Saint-CloudALCINA 2Analysis of Circulating Tumor Markers in Blood
FRANCOIS-CLEMENT BIDARD
- Breast cancerParis, Saint-CloudALCINA-4 (IC 2020-11)Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
LUC CABEL, FRANCOIS-CLEMENT BIDARD
- Paris, Saint-CloudALCYTA (IC 2020-12)Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA
NICOLAS GIRARD
- Saint-CloudALPHABETRandomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer
FRANCOIS-CLEMENT BIDARD
- Saint-CloudAMEBICA - Prodige 38Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.